Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market ...

In fact, the share price is now only right around ... Compared to revenue of $5 billion and $9 billion in cash on the balance sheet, Moderna is an interesting opportunity for a turnaround bet ...

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

In fact, while Moderna ... we have no concerns regarding Moderna's balance sheet. The mRNA treatment landscape is shaping up to be competitive, but the market is also nascent, with the covid ...

The company’s $50M investment from Merck (MRK) strengthens its balance sheet with another strategic ... having extended their contract with Moderna (MRNA), which is now a 10-year contact and ...

Fla., praised news that President Donald Trump will reinstate service members expelled for refusing to take the COVID-19 ...

We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.

This stock can be held in an Investment ISA and an Investment Account ...